Kallyope Inc., a NYC-based biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, raised a $21m expansion of its previously announced Series B financing.
This brings the Series B round total to $87m and total since inception to $131m.
The expanded financing was led by Bill Gates, with participation from previous investors Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital, and Two Sigma Ventures.
The company will use the additional funds to further advance its portfolio of programs targeting the gut-brain axis.
Co-founded by Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D.,and led by Nancy Thornberry, CEO, Kallyope has developed a platform that enables a systematic approach to targeting gut-brain circuits with small molecules and has initiated multiple programs spanning metabolic, central nervous system, and gastrointestinal disorders. In addition to its internal small molecule programs, the companyrecently initiated a collaboration with Novo Nordisk A/S focusing on the discovery of peptide therapeutics for the treatment of obesity and diabetes.
Kallyope is headquartered at the Alexandria Center® for Life Science in New York City.